celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.
Company profile
Ticker
CELC
Exchange
Website
CEO
Brian F. Sullivan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Celcuity LLC
SEC CIK
CELC stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
29 Mar 24
ARS
2023 FY
Annual report to shareholders
29 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27 Mar 24
8-K
Other Events
5 Dec 23
424B3
Prospectus supplement
29 Nov 23
EFFECT
Notice of effectiveness
29 Nov 23
D/A
$2.98 mm in securities to be acquired, sold $2.60 mm, 38 investors
27 Nov 23
Transcripts
CELC
Earnings call transcript
2023 Q4
27 Mar 24
CELC
Earnings call transcript
2023 Q3
13 Nov 23
CELC
Earnings call transcript
2023 Q2
10 Aug 23
CELC
Earnings call transcript
2023 Q1
15 May 23
CELC
Earnings call transcript
2022 Q4
23 Mar 23
CELC
Earnings call transcript
2022 Q3
13 Nov 22
CELC
Earnings call transcript
2022 Q2
13 Aug 22
CELC
Earnings call transcript
2022 Q1
17 May 22
CELC
Earnings call transcript
2021 Q4
24 Mar 22
CELC
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
144
Notice of proposed sale of securities
24 Apr 24
4
Richard E Buller
10 Apr 24
4
Brian F. Sullivan
20 Mar 24
4
Richard E Buller
23 Feb 24
4
Vicky Hahne
15 Feb 24
4
Lance G. Laing
15 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.76 mm | 25.76 mm | 25.76 mm | 25.76 mm | 25.76 mm | 25.76 mm |
Cash burn (monthly) | 2.16 mm | 2.64 mm | 6.30 mm | 4.85 mm | 4.25 mm | 3.73 mm |
Cash used (since last report) | 14.82 mm | 18.14 mm | 43.21 mm | 33.24 mm | 29.15 mm | 25.59 mm |
Cash remaining | 10.94 mm | 7.62 mm | -17.45 mm | -7.48 mm | -3.39 mm | 173.86 k |
Runway (months of cash) | 5.1 | 2.9 | -2.8 | -1.5 | -0.8 | 0.0 |
Institutional ownership, Q3 2023
71.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 61 |
Opened positions | 5 |
Closed positions | 4 |
Increased positions | 19 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 160.39 bn |
Total shares | 21.68 mm |
Total puts | 100.00 |
Total calls | 2.30 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Soleus Capital Master Fund | 2.29 mm | $0.00 |
Venrock Healthcare Capital Partners II | 2.17 mm | $0.00 |
VR Adviser | 2.11 mm | $19.24 bn |
Soleus Capital Management | 2.06 mm | $18.80 bn |
MS Morgan Stanley | 1.97 mm | $17.99 bn |
Commodore Capital | 1.69 mm | $15.48 bn |
Growth Equity Opportunities 18 VGE | 1.52 mm | $15.20 mm |
Ra Capital Management | 1.40 mm | $12.80 bn |
NEA Management | 1.25 mm | $31.79 bn |
BLK Blackrock | 961.52 k | $8.79 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Buller Richard E | Stock Option Common Stock | Gift | Acquire G | Yes | No | 5.5 | 19,558 | 107.57 k | 19,558 |
8 Apr 24 | Buller Richard E | Stock Option Common Stock | Gift | Dispose G | No | No | 5.5 | 19,558 | 107.57 k | 0 |
8 Apr 24 | Buller Richard E | Stock Option Common Stock | Gift | Acquire G | Yes | No | 5.5 | 2,310 | 12.71 k | 2,310 |
8 Apr 24 | Buller Richard E | Stock Option Common Stock | Gift | Dispose G | No | No | 5.5 | 2,310 | 12.71 k | 0 |
8 Apr 24 | Buller Richard E | Stock Option Common Stock | Gift | Acquire G | Yes | No | 5.1 | 12,654 | 64.54 k | 12,654 |
8 Apr 24 | Buller Richard E | Stock Option Common Stock | Gift | Dispose G | No | No | 5.1 | 12,654 | 64.54 k | 0 |
8 Apr 24 | Buller Richard E | Stock Option Common Stock | Gift | Acquire G | Yes | No | 5.5 | 4,555 | 25.05 k | 4,555 |
8 Apr 24 | Buller Richard E | Stock Option Common Stock | Gift | Dispose G | No | No | 5.5 | 4,555 | 25.05 k | 0 |
18 Mar 24 | Sullivan Brian F. | Common Stock | Gift | Acquire G | Yes | No | 0 | 765,897 | 0.00 | 765,897 |
18 Mar 24 | Sullivan Brian F. | Common Stock | Gift | Dispose G | Yes | No | 0 | 765,897 | 0.00 | 189,103 |
News
Needham Reiterates Buy on Celcuity, Maintains $24 Price Target
12 Apr 24
HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $27 Price Target
28 Mar 24
Needham Maintains Buy on Celcuity, Raises Price Target to $24
28 Mar 24
Recap: Celcuity Q4 Earnings
27 Mar 24
Celcuity Q4 EPS $(0.61) Beats $(0.73) Estimate
27 Mar 24